Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{172592,
        author = {Prajwal R. Khandve and Mr. Anil B. Panchal and Pranali S. Dhumal and Mansi U. Kadam and Mahesh A. Nalawade},
        title = {Targeted Liposomal Drug Delivery System},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {9},
        pages = {261-268},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=172592},
        abstract = {Targeted liposomal drug delivery systems are innovative therapeutic strategies designed to enhance the specificity and efficacy of drug treatments. These systems involve the encapsulation of therapeutic agents within liposomes—nano-sized lipid-based vesicles—and functionalizing the liposome surface with targeting ligands. These ligands, such as antibodies or peptides, enable the liposomes to selectively bind to specific cells or tissues, often those involved in diseases like cancer, thereby improving drug accumulation at the desired site of action. This targeted approach minimizes off-target effects, reduces systemic toxicity, and improves the bioavailability of the drug. Liposomal drug delivery systems also offer controlled release profiles, further enhancing therapeutic outcomes. Consequently, they offer great potential for enhancing the accuracy and efficiency of various treatments, especially in cancer therapy and other specialized interventions.},
        keywords = {Targeted liposomes, drug delivery, cancer therapy, nanomedicine, personalized medicine},
        month = {January},
        }